Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1901) 1901
Book Chapter (9) 9
Dissertation (6) 6
Magazine Article (3) 3
Newspaper Article (3) 3
Government Document (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1309) 1309
life sciences & biomedicine (1245) 1245
humans (1029) 1029
animals (948) 948
male (933) 933
female (623) 623
oximes (570) 570
biological and medical sciences (567) 567
medical sciences (546) 546
oximes - pharmacology (483) 483
oximes - administration & dosage (454) 454
rats (418) 418
pharmacology & pharmacy (388) 388
toxicology (361) 361
adult (321) 321
oximes - therapeutic use (319) 319
middle aged (313) 313
mice (290) 290
aged (218) 218
pharmacology. drug treatments (204) 204
melanoma - drug therapy (198) 198
imidazoles - administration & dosage (187) 187
oximes - chemistry (181) 181
technetium tc 99m exametazime (176) 176
acetylcholinesterase (170) 170
dose-response relationship, drug (164) 164
oxime (161) 161
proto-oncogene proteins b-raf - genetics (160) 160
oximes - pharmacokinetics (157) 157
melanoma (153) 153
oximes - adverse effects (152) 152
oncology (151) 151
rats, wistar (150) 150
chemistry (145) 145
acetylcholinesterase - metabolism (140) 140
proto-oncogene proteins b-raf - antagonists & inhibitors (140) 140
neurosciences & neurology (139) 139
biochemistry & molecular biology (138) 138
physical sciences (137) 137
analysis (135) 135
mutation (133) 133
treatment outcome (131) 131
time factors (130) 130
pyrimidinones - administration & dosage (128) 128
cholinesterase reactivators - pharmacology (127) 127
pyridones - administration & dosage (127) 127
organotechnetium compounds (126) 126
poisoning (122) 122
neurosciences (120) 120
tomography, emission-computed, single-photon (116) 116
pyridinium compounds - pharmacology (114) 114
skin neoplasms - drug therapy (111) 111
administration, oral (106) 106
atropine (103) 103
melanoma - genetics (101) 101
chemical and industrial products toxicology. toxic occupational diseases (100) 100
rats, sprague-dawley (99) 99
abridged index medicus (97) 97
antidotes - therapeutic use (96) 96
research (95) 95
antineoplastic combined chemotherapy protocols - therapeutic use (94) 94
organophosphate poisoning (94) 94
adolescent (88) 88
brain - diagnostic imaging (88) 88
cholinesterase inhibitors - toxicity (87) 87
dogs (87) 87
imidazoles - adverse effects (87) 87
dermatology (86) 86
brain - drug effects (83) 83
brain - metabolism (83) 83
cholinesterase reactivators - therapeutic use (83) 83
melanoma - pathology (83) 83
drug therapy, combination (81) 81
imidazoles - therapeutic use (81) 81
neurology (81) 81
oximes - metabolism (81) 81
brain (80) 80
lethal dose 50 (80) 80
care and treatment (79) 79
pyridinium compounds - therapeutic use (78) 78
radiology, nuclear medicine & medical imaging (78) 78
dabrafenib (77) 77
pharmacokinetics (77) 77
structure-activity relationship (77) 77
cholinesterase reactivators - administration & dosage (75) 75
nerve agents (75) 75
pyridinium compounds - administration & dosage (75) 75
health aspects (73) 73
molecular structure (73) 73
organophosphorus compounds (73) 73
atropine - therapeutic use (72) 72
indoles - pharmacology (72) 72
organophosphates (72) 72
toxicity (72) 72
nerve gas (71) 71
atropine - pharmacology (70) 70
chemistry, medicinal (70) 70
enzymes (70) 70
hi-6 (70) 70
skin neoplasms - pathology (70) 70
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1863) 1863
Japanese (26) 26
German (11) 11
Czech (10) 10
French (10) 10
Russian (10) 10
Polish (6) 6
Spanish (5) 5
Croatian (4) 4
Serbian (4) 4
Italian (3) 3
Portuguese (3) 3
Hebrew (2) 2
Bulgarian (1) 1
Chinese (1) 1
Danish (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
by Grob, Jean Jacques, Prof and Amonkar, Mayur M, PhD and Karaszewska, Boguslawa, MD and Schachter, Jacob, Prof and Dummer, Reinhard, Prof and Mackiewicz, Andrzej, Prof and Stroyakovskiy, Daniil, MD and Drucis, Kamil, MD and Grange, Florent, MD and Chiarion-Sileni, Vanna, MD and Rutkowski, Piotr, Prof and Lichinitser, Mikhail, Prof and Levchenko, Evgeny, MD and Wolter, Pascal, MD and Hauschild, Axel, Prof and Long, Georgina V, MD and Nathan, Paul, MD and Ribas, Antoni, Prof and Flaherty, Keith, MD and Sun, Peng, PhD and Legos, Jeffrey J, PhD and McDowell, Diane Opatt, MD and Mookerjee, Bijoyesh, MD and Schadendorf, Dirk, Prof and Robert, Caroline, MD
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Resistance to TRK inhibition mediated by convergent MAPK pathway activation
by Cocco, Emiliano and Schram, Alison M and Kulick, Amanda and Misale, Sandra and Won, Helen H and Yaeger, Rona and Razavi, Pedram and Ptashkin, Ryan and Hechtman, Jaclyn F and Toska, Eneda and Cownie, James and Somwar, Romel and Shifman, Sophie and Mattar, Marissa and Selcuklu, S. Duygu and Samoila, Aliaksandra and Guzman, Sean and Tuch, Brian B and Ebata, Kevin and de Stanchina, Elisa and Nagy, Rebecca J and Lanman, Richard B and Houck-Loomis, Brian and Patel, Juber A and Berger, Michael F and Ladanyi, Marc and Hyman, David M and Drilon, Alexander and Scaltriti, Maurizio
Nature medicine, ISSN 1078-8956, 09/2019, Volume 25, Issue 9, pp. 1422 - 1427
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Mitogen-Activated Protein Kinase Kinases - genetics | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Cell-Free Nucleic Acids - drug effects | Male | Cell-Free Nucleic Acids - genetics | Indazoles - administration & dosage | Molecular Targeted Therapy | Young Adult | Pyridones - administration & dosage | Benzamides - administration & dosage | Heterografts | Neoplasms - genetics | Adult | Female | Child | Pyrimidines - administration & dosage | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Clinical Trials as Topic | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Pyrazoles - administration & dosage | Animals | MAP Kinase Signaling System - drug effects | Oncogene Proteins, Fusion - genetics | Adolescent | Receptor, trkA - genetics | Cell Proliferation - drug effects | Mice | Pyrimidinones - administration & dosage | Neoplasms - pathology | Drug Resistance, Neoplasm - drug effects | MAP kinase | Kinases | Disease control | Patients | Convergence | Alterations | Addiction | Protein kinase | Delay time | Solid tumors | Inhibition | Mutation | Target acquisition | Tumors | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
by Long, G. V and Flaherty, K. T and Stroyakovskiy, D and Gogas, H and Levchenko, E and de Braud, F and Larkin, J and Garbe, C and Jouary, T and Hauschild, A and Chiarion-Sileni, V and Lebbe, C and Mandala, M and Millward, M and Arance, A and Bondarenko, I and Haanen, J. B. A. G and Hansson, J and Utikal, J and Ferraresi, V and Mohr, P and Probachai, V and Schadendorf, D and Nathan, P and Robert, C and Ribas, A and Davies, M. A and Lane, S. R and Legos, J. J and Mookerjee, B and Grob, J. -J
Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | trametinib | durable outcomes | metastatic | melanoma | BRAF | Original | dabrafenib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
by Falchook, Gerald S, Dr and Long, Georgina V, PhD and Kurzrock, Razelle, Prof and Kim, Kevin B, MD and Arkenau, Tobias H, PhD and Brown, Michael P, PhD and Hamid, Omid, MD and Infante, Jeffrey R, MD and Millward, Michael, MD and Pavlick, Anna C, MD and O’Day, Steven J, MD and Blackman, Samuel C, PhD and Curtis, C Martin, BA and Lebowitz, Peter, PhD and Ma, Bo, PhD and Ouellet, Daniele, PhD and Kefford, Richard F, Prof
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Neurology | General aspects | Tumors of the nervous system. Phacomatoses | Dermatology | Biological and medical sciences | Medical sciences | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma
by Hauschild, Axel and Dummer, Reinhard and Schadendorf, Dirk and Santinami, Mario and Atkinson, Victoria and Mandalà, Mario and Chiarion-Sileni, Vanna and Larkin, James and Nyakas, Marta and Dutriaux, Caroline and Haydon, Andrew and Robert, Caroline and Mortier, Laurent and Schachter, Jacob and Lesimple, Thierry and Plummer, Ruth and Dasgupta, Kohinoor and Haas, Tomas and Shilkrut, Mark and Gasal, Eduard and Kefford, Richard and Kirkwood, John M and Long, Georgina V
Journal of clinical oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 35, pp. 3441 - 3449
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus | Rapid Communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Management of Treatment‐Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
by Daud, Adil and Tsai, Katy
The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study
by Luke, Jason J and Ghate, Sameer R and Kish, Jonathan and Lee, Choo Hyung and McAllister, Lindsay and Mehta, Sonam and Ndife, Briana and Feinberg, Bruce A
Future oncology (London, England), ISSN 1479-6694, 09/2019, Volume 15, Issue 25, pp. 2933 - 2942
Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Molecular Targeted Therapy | Pyridones - administration & dosage | Vemurafenib - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Melanoma - genetics | Immunotherapy | Female | Ipilimumab - administration & dosage | Piperidines - administration & dosage | Treatment Outcome | Melanoma - pathology | CTLA-4 Antigen - immunology | Mutation - genetics | Disease-Free Survival | Azetidines - administration & dosage | Melanoma - immunology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyrimidinones - administration & dosage | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Nivolumab - administration & dosage
Journal Article
Details down arrow
8. Full Text Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
by Cohen Aubart, Fleur and Emile, Jean-François and Carrat, Fabrice and Charlotte, Frédéric and Benameur, Neila and Donadieu, Jean and Maksud, Philippe and Idbaih, Ahmed and Barete, Stéphane and Hoang-Xuan, Khê and Amoura, Zahir and Haroche, Julien
Blood, ISSN 0006-4971, 09/2017, Volume 130, Issue 11, pp. 1377 - 1380
Life Sciences & Biomedicine | Hematology | Science & Technology | Erdheim-Chester Disease - diagnostic imaging | Follow-Up Studies | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Oximes - therapeutic use | Molecular Targeted Therapy | Indoles - administration & dosage | Multicenter Studies as Topic | Registries | Retrospective Studies | Imidazoles - therapeutic use | France | Erdheim-Chester Disease - genetics | Piperidines - administration & dosage | Drug Administration Schedule | Treatment Outcome | Positron Emission Tomography Computed Tomography | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Erdheim-Chester Disease - drug therapy | Azetidines - administration & dosage | Azetidines - therapeutic use | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Indoles - therapeutic use | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Antimüllerian hormone levels decrease in women using combined contraception independently of administration route
by Kallio, Sanna, M.D and Puurunen, Johanna, M.D and Ruokonen, Aimo, M.D., Ph.D and Vaskivuo, Tommi, M.D., Ph.D and Piltonen, Terhi, M.D., Ph.D and Tapanainen, Juha S., M.D., Ph.D
Fertility and sterility, ISSN 0015-0282, 2013, Volume 99, Issue 5, pp. 1305 - 1310
Internal Medicine | Obstetrics and Gynecology | combined contraception | follicle development | Antimüllerian hormone | FSH | inhibin B | Life Sciences & Biomedicine | Obstetrics & Gynecology | Reproductive Biology | Science & Technology | Norgestrel - administration & dosage | Prospective Studies | Humans | Contraceptive Devices, Female | Oximes - administration & dosage | Administration, Cutaneous | Follicle Stimulating Hormone, Human - blood | Young Adult | Desogestrel - administration & dosage | Ovarian Follicle - drug effects | Adult | Female | Norgestrel - analogs & derivatives | Ethinyl Estradiol - administration & dosage | Anti-Mullerian Hormone - blood | Contraceptives, Oral, Combined - administration & dosage | Estrogens - administration & dosage | Pituitary Gland - drug effects | Oral contraceptives | Usage | Hormones | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
by Robert, Caroline and Karaszewska, Boguslawa and Schachter, Jacob and Rutkowski, Piotr and Mackiewicz, Andrzej and Stroiakovski, Daniil and Lichinitser, Michael and Dummer, Reinhard and Grange, Florent and Mortier, Laurent and Chiarion-Sileni, Vanna and Drucis, Kamil and Krajsova, Ivana and Hauschild, Axel and Lorigan, Paul and Wolter, Pascal and Long, Georgina V and Flaherty, Keith and Nathan, Paul and Ribas, Antoni and Martin, Anne-Marie and Sun, Peng and Crist, Wendy and Legos, Jeff and Rubin, Stephen D and Little, Shonda M and Schadendorf, Dirk
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights